Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - hidroklorotiazid; losartan - filmsko obložena tableta - hidroklorotiazid 12,5 mg / 1 tableta  losartan45,76 mg / 1 tableta; losartan 45,76 mg / 1 tableta - losartan in diuretiki

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - hidroklorotiazid; losartan - filmsko obložena tableta - hidroklorotiazid 25 mg / 1 tableta  losartan91,52 mg / 1 tableta; losartan 91,52 mg / 1 tableta - losartan in diuretiki

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

iris d.o.o. - raztopina za kožni vbodni test - alergijski testi

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lenis d.o.o. - raztopina za kožni vbodni test - alergijski testi

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

gedeon richter plc. - dienogest; etinilestradiol - filmsko obložena tableta - dienogest 2 mg / 1 tableta  etinilestradiol0,03 mg / 1 tableta; etinilestradiol 0,03 mg / 1 tableta - dienogest in etinilestradiol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lenis d.o.o. - raztopina za kožni vbodni test - alergijski testi

Evropska unija - slovenščina - EMA (European Medicines Agency)

bayer ag - riociguat - hipertenzija, pljučnica - antihipertenzivi za pljučno arterijsko hipertenzijo - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. učinkovitosti je bil prikazan v pah prebivalstva, vključno z aetiologies z idiopatsko ali dedne pah ali pah, povezanih z vezivnega tkiva bolezni. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Evropska unija - slovenščina - EMA (European Medicines Agency)

biogen netherlands b.v.  - interferon beta-1a - multiple skleroza - immunostimulants, - avonex je primerna za zdravljenje:bolnikov, diagnosticiranih z recidivno multiplo sklerozo (ms). v kliničnih preskušanjih, to je bilo značilno, da dva ali več akutna exacerbations (recidivi) v preteklih treh letih, brez dokazov za stalno napredovanje med zagonov; avonex upočasni napredovanje invalidnosti in zmanjša pogostost zagonov;bolniki z enim demielinizirajoče dogodek z aktivno vnetni proces, če je dovolj resen, da bi lahko jamčili zdravljenje z intravensko kortikosteroidi, če alternativne diagnoze so bile izključene, če so odločeni, da se na visoko tveganje za razvoj klinično dokončne ms. avonex je treba prekiniti pri bolnikih, ki razvijejo postopno ms.

Evropska unija - slovenščina - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi b.v. - tirotropin alfa - Širokopasemske neoplazme - spodnjega režnja hipofize hormoni in analogi, hipofize in hypothalamic hormoni in analogi - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.